Navigation Links
PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
Date:3/9/2010

ANNAPOLIS, Md., March 9 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Company will present at the Roth Capital Partners Growth Stock Conference in Laguna Niguel, California on Monday, March 15, 2010 at 1:30 p.m. P.T. To access the Company's presentation via webcast, go to:  http://www.wsw.com/webcast/roth23/pip/.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
2. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
3. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
4. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
5. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
6. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
7. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
8. PharmAthene Reports Second Quarter 2009 Financial and Operational Results
9. PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009
10. PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
11. PharmAthenes 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today ... 30, 2015, corporate highlights, and near-term milestones.  The ... at www.sedar.com ,  www.edgar.com and ... expects to launch its RCS-01 treatment for aging ...
(Date:8/27/2015)... ... August 27, 2015 , ... The ... funds, investment firms and animal health companies to hear from animal health companies ... Several have also received licensing agreements or distribution contracts. This meeting is ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
(Date:8/27/2015)... 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... ended June 30, 2015. Biorem,s complete second quarter financial statements and ... FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended , Six -months ... , 2015 , 2014 Revenue , 4,709 ... 4,433 Gross profit , 1,656 , 56 ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3
... and product pipeline, BOTHELL, WA and VANCOUVER, ... OGXI ), a biopharmaceutical company committed,to the development ... in the treatment of cancer, today reported unaudited ... ended September 30, 2008., Third Quarter 2008 ...
... TEL AVIV, Israel, November 10 InspireMD, developers ... that MGuard(TM),was successfully implanted in a complex lesion ... procedure was performed by Dr. Dariusz Dudek and ... Symposium,"A New Approach to Treating Thrombus Containing Lesions ...
... ANGELES, November 10 , - Current Treatment Fails ... Risk Reduction Initiative (R3i) Calls for Action to Reduce,the ... in Millions of Patients With Heart Disease and Diabetes, ... Japan have come together today to launch the Residual ...
Cached Biology Technology:OncoGenex Reports Third Quarter Financial Results 2OncoGenex Reports Third Quarter Financial Results 3OncoGenex Reports Third Quarter Financial Results 4OncoGenex Reports Third Quarter Financial Results 5OncoGenex Reports Third Quarter Financial Results 6OncoGenex Reports Third Quarter Financial Results 7OncoGenex Reports Third Quarter Financial Results 8OncoGenex Reports Third Quarter Financial Results 9MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 2MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 3MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 4Unique New Initiative by World-Recognized Specialists in Heart Disease and Diabetes to Reduce Residual Vascular Risk Launched Today 2Unique New Initiative by World-Recognized Specialists in Heart Disease and Diabetes to Reduce Residual Vascular Risk Launched Today 3
(Date:8/11/2015)... 11, 2015 Today, ZUK announced its Android ... well as expected revenues in 2015 that relate to sales of ... guidance of approximately 2,200 MSEK for 2015. Jörgen Lantto, ... prominent smartphone manufacturer in China ... selected FPC1 155 for Z1 ...
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
(Date:8/4/2015)... ALBANY, N.Y., Aug. 4, 2015  AMRI (NASDAQ: AMRI ) ... June 30, 2015. Highlights: , Second quarter ... increase from 2014 , Adjusted contract margins of ... EPS of $0.22, including a $0.05 decrease in EPS from royalties ... of $16 million "We are very pleased to ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... An international team of researchers led by a ... two genes linked to a disabling form of ... disease in which some or all of the ... the association of two genes implicated in Graves ...
... fossil tracks belonging to large, carnivorous dinosaurs have been ... Monash University and the Museum of Victoria (both in ... large dinosaurs were living in a polar environment during ... Antarctica and close to the South Pole. The ...
... Research Development Program scientific advisory board approved a ... tropical dry forests where military training is conducted ... Environmental Research Development Program is a part of ... the environmental impact of military operations. Research scientists ...
Cached Biology News:Study reveals 2 genes linked to disabling arthritis 2Study reveals 2 genes linked to disabling arthritis 3Emory paleontologist reports discovery of carnivorous dinosaur tracks in Australia 2Research approved for Hawaiian military training area 2
... [RS17 ] to PRKAR2 cAMP is ... of cellular functions. cAMP exerts its effects ... which transduces the signal through phosphorylation of ... AMPK is a tetramer composed of two ...
...
... a Perkin Elmer UltraVIEW system and want to ... and iQ software? No problem. Our experienced ... your existing microscope, lasers, Sutter filter wheel, Piezo ... work with our precision controller unit and workstation... ...
... Dyad instrument is the most advanced thermal ... world-class thermal performance, the Dyad also boasts ... as point-and-click navigation via touch pad or ... easily and economically expanded to a four-bay ...
Biology Products: